Multiple Myeloma

Excellence Forum

Leaders in the field sharing authoritative insights and institutional best practices.

Videos

Recent Advancements in Myeloma Treatment Changing the Standard of Care

04/04/2024

Featuring Hamza Hashmi, MD

Hamza Hashmi, MD, Memorial Sloan Kettering Cancer Center, shares insights on recent advancements in myeloma treatment and gives a preview of his session on managing myeloma at the 2024 Community Oncology Conference.

Hamza Hashmi, MD, Memorial Sloan...

04/04/2024

Journal of Clinical Pathways

Videos

Strategies for Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma

02/13/2024

Featuring Suzanne Lentszch, MD, PhD

Featuring Suzanne Lentszch, MD, PhD ...

At the 2023 Lymphoma, Leukemia & Myeloma Congress in New York, New York, Suzanne Lentszch, MD, PhD, discusses the management of high-risk, newly diagnosed multiple myeloma.

At the 2023 Lymphoma, Leukemia &...

02/13/2024

Lymphoma, Leukemia & Myeloma Network

Videos

The Use of Clinical Pathways in the Treatment of Patients With Multiple Myeloma

11/14/2022

Nisha Joseph, MD, discusses antibodies in myeloma and the use of clinical pathways in the treatment of patients with multiple myeloma, touching on new, “ever-evolving” therapeutics and recent drug approvals in the multiple myeloma space.

Nisha Joseph, MD, discusses...

11/14/2022

Journal of Clinical Pathways

Videos

PFS and Depth of Response Associated With Isatuximab Plus Carfilzomib and Dexamethasone in Patients With Multiple Myeloma

08/17/2022

Winston Wong, PharmD, discusses results from the IKEMA trial, a randomized, open-label, multicenter phase 3 study comparing isatuximab plus carfilzomib and dexamethasone vs carfilzomib and dexamethasone in patients with relapsed multiple...

Winston Wong, PharmD, discusses...

08/17/2022

Journal of Clinical Pathways

Interview

Isatuximab Plus Carfilzomib and Dexamethasone Improves PFS in Multiple Myeloma

07/20/2022

Marcelo Capra, MD, discusses results from a study comparing the benefit of progression-free survival associated with isatuximab in combination with carfilzomib and dexamethasone vs carfilzomib and dexamethasone among patients with relapsed...

Marcelo Capra, MD, discusses...

07/20/2022

Journal of Clinical Pathways

Interview

Isatuximab Plus Carfilzomib and Dexamethasone for Relapsed MM: Results From the IKEMA Trial

03/30/2022

Thomas Martin, MD, discusses results from the IKEMA trial, which explored the addition of isatuximab to carfilzomib and dexamethasone for patients with relapsed MM.

Thomas Martin, MD, discusses...

03/30/2022

Journal of Clinical Pathways

Videos

Real-World Treatments and Outcomes of Triple-Class Relapsed or Refractory MM

01/11/2022

Christopher Kim, PhD, MPH, discusses findings from a study which evaluated treatment and outcomes among patients with triple-class relapsed or refractory MM in US community practice.

Christopher Kim, PhD, MPH,...

01/11/2022

Journal of Clinical Pathways

Videos

All4Cure: Patient Data Aggregate Platform for Collaborative Multiple Myeloma Care

03/05/2021

Tony Blau, MD, Founder and CEO, provides a demonstration of All4Cure, discusses the vision and need for the platform, and describes its ability to improve patient care.

Tony Blau, MD, Founder and CEO,...

03/05/2021

Journal of Clinical Pathways

Videos

IRd vs Placebo-Rd for Patients With Newly-Diagnosed MM

12/20/2020

Journal of Clinical Pathways

$Real-World Comparison of DRd and DPd for Relapsed/Refractory MM$

Videos

Real-World Comparison of DRd and DPd for Relapsed/Refractory MM

12/09/2020

Muhamad Alhaj Moustafa, MD, presents findings from a study comparing daratumumab plus lenalidomide and dexamethasone (DRd) vs daratumumab plus pomalidomide and dexamethasone (DPd) for lenalidomide-exposed patients with relapsed or refractory...

Muhamad Alhaj Moustafa, MD,...

12/09/2020

Journal of Clinical Pathways

Current Issue

June 2024

Volume 10

Issue 3

Current Issue

Issue Archive

Special Reports

Sponsored

Special Report

Shedding Light on Non-Small Cell Lung Cancer & Its Impact on Patients

04/03/2023

This supplement aims to raise awareness about non-small cell lung cancer (NSCLC) and its impact on patients by providing comprehensive information to help improve early detection and appropriate care.

This supplement aims to raise...

04/03/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Brukinsa® (Zanubrutinib) for Chronic Lymphocytic Leukemia

03/31/2023

In this product monograph, read an interview with Jeff P. Sharman, MD, as he discusses important BRUKINSA® trial data including efficacy, safety, dosing, administration, and other relevant data. These key findings supported the Food and Drug...

In this product monograph, read...

03/31/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Tumor Lysis Syndrome: Early Diagnosis and Management

01/04/2023

This review summarizes the diagnosis, pathophysiology, and evidence-based guidelines for the prevention and management of tumor lysis syndrome, a common, acute, life-threatening disease primarily in patients with hematologic cancers and solid...

This review summarizes the...

01/04/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

A Tumor Lysis Syndrome Risk Assessment and Its Impact on Patients

08/09/2022

In an interview with Journal of Clinical Pathways, Nicholas Short, MD, shares objectives on the design and benefits of MD Anderson’s Tumor Lysis Syndrome clinical assessment for patient risk and impact on patient care.

In an interview with Journal of...

08/09/2022

Journal of Clinical Pathways

Updated NCCN Guidelines on B-Cell Lymphomas

Sponsored

JCP Special Report

Overview of the Updated NCCN Guidelines on B-Cell Lymphomas

06/15/2022

Robert Fee

Updated multiple times in 2022, the National Comprehensive Cancer Network (NCCN) Guidelines for B-Cell Lymphomas provide recommendations for the prevention, diagnosis, and management of malignancies.

Updated multiple times in 2022,...

06/15/2022

Journal of Clinical Pathways

Sponsored

Special Report

Expanded Indication for Zanubrutinib: Marginal Zone Lymphoma and Waldenström’s Macroglobulinemia

06/10/2022

In an interview with Journal of Clinical Pathways, Mitul Gandhi, MD, reviews the clinical impact and treatment approaches and challenges for patients with marginal zone lymphoma and Waldenström’s macroglobulinemia.

In an interview with Journal of...

06/10/2022

Journal of Clinical Pathways

JCP Special Report

Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group

05/20/2022

Winston Wong, PharmD

Gordon Kuntz

Robin T Zon, MD, FACP, FASCO

2021 Care Pathways Working Group

The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...

The Journal of Clinical Pathways...

05/20/2022

Journal of Clinical Pathways

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

Sponsored

Special Report

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

12/15/2021

Deborah Abrams Kaplan

NCCN released updates to its practice guidelines on treating triple-negative breast cancer, featuring updates on sacituzumab govitecan recommendations and more.

NCCN released updates to its...

12/15/2021

Journal of Clinical Pathways

Sponsored

Special Report

Navigating the Patient Journey for Unresectable Stage III Non-Small Cell Lung Cancer

09/16/2021

.ryan-test { display: none; } .body-content h3 { font-size: 18px; line-height: 18px; color: #000000; font-weight: 600px; } .related-content { display: none; } .body-content div > div:nth-of-type(3) .paragraph > h3 >...

.ryan-test { display:...

09/16/2021

Journal of Clinical Pathways

$Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma$

Special Report

Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma

01/14/2021

Journal of Clinical Pathways

Journal of Clinical Pathways Newsletter

Recent Stories

Videos

Recent Advancements in Myeloma Treatment Changing the Standard of Care

04/04/2024

Featuring Hamza Hashmi, MD

Hamza Hashmi, MD, Memorial Sloan...

04/04/2024

Journal of Clinical Pathways

Videos

Strategies for Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma

02/13/2024

Featuring Suzanne Lentszch, MD, PhD

Featuring Suzanne Lentszch, MD, PhD ...

At the 2023 Lymphoma, Leukemia & Myeloma Congress in New York, New York, Suzanne Lentszch, MD, PhD, discusses the management of high-risk, newly diagnosed multiple myeloma.

At the 2023 Lymphoma, Leukemia &...

02/13/2024

Lymphoma, Leukemia & Myeloma Network

Videos

The Use of Clinical Pathways in the Treatment of Patients With Multiple Myeloma

11/14/2022

Nisha Joseph, MD, discusses...

11/14/2022

Journal of Clinical Pathways

Videos

PFS and Depth of Response Associated With Isatuximab Plus Carfilzomib and Dexamethasone in Patients With Multiple Myeloma

08/17/2022

Winston Wong, PharmD, discusses...

08/17/2022

Journal of Clinical Pathways

Interview

Isatuximab Plus Carfilzomib and Dexamethasone Improves PFS in Multiple Myeloma

07/20/2022

Marcelo Capra, MD, discusses...

07/20/2022

Journal of Clinical Pathways

Multiple Myeloma Excellence Forum

Current Issue

Special Reports

Subscribe

Recent Stories

Specialties

Events

Year Round Education

HMP Global Products